Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Introduction Mitotic kinases play an essential role in mitos
2023-04-26

Introduction Mitotic kinases play an essential role in mitosis, Aurora and other mitotic kinases are often observed over-expression in human solid and many hematologic cancers. As one of serine/threonine kinases, Aurora kinase family is involved in centrosome maturation, mitotic spindle formation,
-
cAMPS-Rp, triethylammonium salt sale We subsequently perform
2023-04-25

We subsequently performed immunohistochemistry on sections obtained from mice at 16 weeks after surgery. Type II collagen expression was detected in all articular cartilage zones, but was weak in the upper zone in the vehicle-treated group. MMP-13 and type X collagen expression were increased in the
-
br Materials and methods br Results br Discussion Recently w
2023-04-25

Materials and methods Results Discussion Recently, we showed that stimulation of TRPM3 and TRPC6 channels triggers a signaling cascade leading to the activation of AP-1 [11], [12], [13], [15]. The objective of this study was to investigate whether stimulation of TRPV1 channels leads to an a
-
HMGA proteins have also been linked to localized changes in
2023-04-25

HMGA proteins have also been linked to localized changes in chromatin/nucleosome structure and alterations of cellular phenotype during induction of gene transcription in activated T lymphocytes. An adaptive immune response is initiated when naïve resting T lymphocytes encounter their corresponding
-
Zoniporide hydrochloride br Acknowledgments br Introduction
2023-04-25

Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the
-
br Discussion Herein we demonstrate that mice deficient in L
2023-04-25

Discussion Herein, we demonstrate that mice deficient in L-12/15 LO are more sensitive to 3-NP-induced toxicity although a substantial individual variability in striatal lesion size in response to 3-NP in both genotypes was observed. This variability is not atypical; several studies demonstrate s
-
br KYN Acts on AhR To Induce
2023-04-25

KYN Acts on AhR To Induce Tolerogenic Immunity IDO1 and TDO2 are intracellular heme-containing metalloproteins that catalyze the committing and rate-limiting step of the KYN pathway (KP) that converts the essential amino ML133 HCl tryptophan to a series of biologically active second metabolites
-
amitriptyline hydrochloride receptor In particular we focuse
2023-04-25

In particular, we focused our attention on beta2 adrenergic receptors, since their commercial inhibitors are effective in lowering IOP, the primary indication of glaucoma. The hypotensive action of a commercial sequence of beta2 adrenergic receptor siRNA was tested in rabbits. The results confirmed
-
br Conflict of Interest br Transparency Document br Introduc
2023-04-25

Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is
-
Alisol B 23-acetate Here we report discovery of
2023-04-25

Here we report discovery of highly selective pan-Aurora kinase inhibitors through phenotypic screening. The co-crystal structure of Alisol B 23-acetate bound in the ATP binding site of Aurora A is described, and provides insight into the possible structural basis for the selectivity of the interac
-
The Type A series contains of the
2023-04-25

The Type-A series contains 6 of the 11 confirmed hits, making it a highly attractive lead template. Seven (7) out of 8 Type-A series of 3-substituted-2-furoic acids are highly active (84–100% inhibition) at the high concentration of 100μM. We could deduce some interesting, albeit preliminary structu
-
The incremental reduction albeit not statistically
2023-04-21

The incremental reduction, albeit not statistically significant, in collagen I with LCZ696 compared to perindopril treated animals, may therefore be related to a more compliant ventricle in LCZ696-treated animals. This is not so surprising given the incremental anti-fibrotic effect of the active met
-
In addition unconventional mechanisms of internalization can
2023-04-21

In addition, unconventional mechanisms of internalization cannot be ignored. It is generally believed that the conventional homologous internalization of a GPCR depends on the activation of G proteins, since GRK activation requires the pre-activation of G proteins (Fig. 2). Feng et al. demonstrated
-
Amyloid fibrils are insoluble high molecular weight non crys
2023-04-21

Amyloid fibrils are insoluble, high-molecular-weight, non-crystalline aggregates and traditional experimental techniques for structure determination such as X-ray and solution NMR cannot resolve their high resolution structures [64], [68]. However, amyloid fibrils exhibit various advantageous featur
-
br Development of lorlatinib from crizotinib
2023-04-21

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
15388 records 342/1026 page Previous Next First page 上5页 341342343344345 下5页 Last page